70 results
Page 2 of 4
8-K
EX-99.2
1zdak8ocj8bcdi4jc5ot
18 May 22
Passage Bio Presents New Interim Clinical and Biomarker
7:16am
8-K
EX-99.2
5xh5doc1h
16 May 22
Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights
7:15am
POS AM
62c0cvxw
3 Mar 22
Prospectus update (post-effective amendment)
8:29am
POSASR
k0cl0pot psj6wx0g
3 Mar 22
Automatic shelf registration (post-effective amendment)
7:00am
8-K
EX-99.2
n827 yd9nrodl
11 Feb 22
Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium
11:00am
8-K
EX-99.2
okhk8
10 Jan 22
Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline
8:00am
8-K
EX-99.2
ug97dh2g 6n7cqu3v9z
17 Dec 21
Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis
7:01am
8-K
EX-99.2
cikrehoplcod pxq
4 Nov 21
Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business Highlights
8:00am
8-K
EX-99.1
vhw04x7y9myvvstq3
4 Oct 21
Regulation FD Disclosure
7:31am
8-K
EX-99.2
bdm7ec9t69nayv ae
5 Aug 21
Passage Bio Reports Second Quarter 2021 Financial Results and Provides Recent Business Highlights
7:01am
8-K
EX-99.2
b62zu rx9g
5 May 21
Passage Bio Reports First Quarter 2021 Financial Results and Recent Business Highlights
7:00am